The 6th CHD-Indonesia teleconference
Program |
Mailing List |
Connection Information |
Files |
Report |
ver 1.55
* For more information, please refer to the TEMDEC policy.
The 6th CHD-Indonesia teleconference
Local Time at Main Venue | 2018.03.05(Mon) 10:30 - 60min, Kanagawa, JP (UTC+09:00) |
Organizer | Toshihide Asou |
Topic | Surgical Treatment of Atrioventricular Septal Defect |
Contents | Pediatrics |
Style | Conference |
Connection Method | Vidyo |
Server At | Kyushu University |
Access Information | - |
Brief Description | First of all, I like to announce that Dr. Dicky Fahkry, one of our main members of this teleconference, has become the director of RS Jantung Harapan Kita. We would cerebrate this big news which will provide good gain and luck to Indonesian people with heart disease. In addition, new members have joined us, and this also will make great progress our teleconference and hopefuly pediatric cardiac care in Indonesia. Then, we hope to have their self-introduction and their expectations on this teleconference. In the present teleconference, an interesting topic will be the current practice of the treatment of atrioventricular septal defect (AVSD). Repair of complete AVSD has been mostly recommended at the earlier age of 3 to 6 months, and excellent outcomes has been reported. However, when the surgery is performed at the later period, a high rate of mortality and morbidity after repair in cAVSD have been reported. Usefulness of pulmonary artery banding can be considered as one of surgical options for late comers with cAVSD to adjust and control the pulmonary artery beds to the good conditions. Then, good surgical outcomes of partial AVSD have been reported at the viewpoint of mortality. Some reports, however, have still revealed the high rate of redo for residual AV valve regurgitation after surgery of partial AVSD. |
Key Members
Chair | Toshihide Asou | National Cardiovascular Center Harapan Kita | ID |
Co-Chair 1 | - | - | - |
Co-Chair 2 | - | - | - |
Chief Engineer 1 | Motoyoshi Kawataki | Kanagawa Children's Medical Center | JP |
Chief Engineer 2 | Yoshiko Houkabe | Kyushu University Hospital | JP |
Chief Engineer 3 | - | - | - |
Chief Engineer 4 | - | - | - |
Connecting Institutions
Red is to be decidedCity, Country | Institution | Moderator | Local Engineer | |
---|---|---|---|---|
1(Main). | Kanagawa, JP | Kanagawa Children's Medical Center | Toshihide Asou | Motoyoshi Kawataki |
2. | Jakarta, ID | National Cardiovascular Center Harapan Kita | Anna Rahayoe | Budi Rahmat |
3. | Pekanbaru, ID | Pekanbaru Eka hospital | Shirley L Anggriawan | Suyetno |
4. | Jakarta, ID | University of Indonesia | Rubiana Sukardi | Sukris Dianto |
Schedule
Main venue | Localtime | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1.Kanagawa, JP (UTC+09:00) | Contents | Presenter | UTC+07:00 (Institution No. 2, 3, 4) | |||||||||||||||||||
2018.03.05 09:30 - 10:30 | Connecting starts | 2018.03.05 07:30 - 08:30 | ||||||||||||||||||||
10:30 - 10:45 | Speech by Dicky and self-introduction by the new members | Toshihide Asou(Kanagawa Children's Medical Center) | 08:30 - 08:45 | |||||||||||||||||||
10:45 - 11:00 | Surgical treatment of AVSD in RSJHK | Dr. Salomo Purba(National Cardiovascular Center Harapan Kita) | 08:45 - 09:00 | |||||||||||||||||||
11:00 - 11:15 | Current Role of PAB in the treatment of complete AVSD | Mariko Kobayashi(Kanagawa Children's Medical Center) | 09:00 - 09:15 | |||||||||||||||||||
11:15 - 11:30 | Surgical outcomes of partial AVSD in KCMC | Mariko Kobayashi(Kanagawa Children's Medical Center) | 09:15 - 09:30 | |||||||||||||||||||
11:30 - 11:30 | Closing remarks | Toshihide Asou(Kanagawa Children's Medical Center) | 09:30 - 09:30 |
Precautions
- The conference will be recorded by the photos and movies.
- Pictures taken at the conference will be published in TEMDEC home page, annual report and conference presentations.
- Do not present the personal information of patients any in oral and presentation materials without obtaining the patient's consent.
* For more information, please refer to the TEMDEC policy.